文献速递胃肠外科围术期管理与 ERAS

食管腺癌病理完全缓解后FLOT与CROSS方案的生存比较

FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma.
PubMed 文献 · JAMA Surg · 2026-01-01

这项多中心队列研究纳入297例新辅助治疗后达病理完全缓解(pCR)并接受根治性食管切除术的食管或胃食管交界腺癌患者,比较围术期FLOT化疗与CROSS放化疗的长期结局。提示pCR的预后意义可能因新辅助模式而异。

要点

  • pCR后FLOT组总生存优于CROSS组(校正HR 0.34,95%CI 0.16-0.69)。
  • FLOT组复发率8.8%,低于CROSS组的24.7%。
  • CROSS组复发以远处转移为主(70.3%),FLOT组复发模式更异质。

核心结论

  • 在达到pCR的食管腺癌患者中,围术期FLOT较CROSS与更优生存、更低复发风险和更晚复发相关。
  • pCR的预后意义可能因新辅助治疗模式不同而有所差异,应结合治疗策略解读。

研究设计与样本

  • 多中心队列研究,在14家欧洲高容量食管胃癌中心开展,时间跨度为2018年1月至2024年12月。
  • 共2717例 eligible 患者,其中297例达到pCR并纳入分析(平均[SD]年龄64.4[9.7]岁;256例[79.5%]为男性)。
  • 150例接受CROSS,147例接受FLOT;随访从手术至死亡或末次接触。

主要发现

  • 未校正分析中,FLOT与更优总生存相关(HR 0.32;95%CI 0.17-0.60;P<.001),与更优无病生存相关(HR 0.32;95%CI 0.19-0.55;P<.001)。
  • 校正后FLOT仍独立与更优总生存相关(HR 0.34;95%CI 0.16-0.69;P=.003),与更优无病生存相关(HR 0.35;95%CI 0.19-0.62;P<.001)。
  • FLOT组复发13/147例(8.8%),CROSS组复发37/150例(24.7%)。
  • CROSS组复发以远处转移为主(37例复发中27例[70.3%]);FLOT组复发模式更异质(13例复发中局部区域2例[15.4%]、远处2例[38.5%]、两者兼有6例[30.8%])。
  • FLOT组中位复发时间较CROSS组更长(16.8[12.3-21.5]个月 vs 12.8[7.1-26.7]个月)。

关键数值与推荐

  • 亚组分析中,FLOT在cN0或cN1疾病中与更好生存相关(HR 0.32;95%CI 0.15-0.67;P=.002)。

临床怎么用

  • 对于新辅助治疗后达到pCR的食管腺癌患者,选择FLOT而非CROSS可能与更优长期生存和更低复发风险相关。
  • pCR后应结合所采用的新辅助治疗模式评估预后,并据此制定随访策略。

局限性

  • 为队列研究,非随机对照,可能存在残余混杂。
  • FLOT组患者更年轻且基线临床淋巴结阳性比例更高,两组基线特征存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pathological complete response (pCR) following neoadjuvant therapy is associated with favorable prognosis in esophageal adenocarcinoma. However, whether long-term outcomes differ by neoadjuvant modality among patients achieving pCR remains uncertain. OBJECTIVE: To compare survival outcomes and recurrence patterns in patients with esophageal or gastroesophageal junction adenocarcinoma achieving pCR after perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy vs the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study protocol (CROSS). DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted at 14 high-volume European esophagogastric cancer centers between January 2018 and December 2024 with follow-up from surgery to death or last contact among patients with esophageal or junctional adenocarcinoma treated with neoadjuvant therapy followed by curative esophagectomy. Patients with squamous carcinoma, noncurative resection, incomplete pathological response, or 90-day mortality were excluded. EXPOSURE: Neoadjuvant perioperative FLOT chemotherapy or CROSS chemoradiotherapy followed by curative-intent esophagectomy. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival. Secondary outcomes included disease-free survival, recurrence patterns, and nodal stage-stratified survival. Survival was estimated using Kaplan-Meier methods and multivariable Cox proportional hazards models. RESULTS: Among 2717 eligible patients, 297 achieved pCR and were analyzed (mean [SD] age, 64.4 [9.7] years; 256 [79.5%] men). Of these, 150 received CROSS and 147 FLOT. FLOT patients were younger and more frequently clinically node-positive at baseline, while postoperative outcomes were similar. On unadjusted analysis, FLOT was associated with better overall survival (hazard ratio [HR], 0.32; 95% CI, 0.17-0.60; P < .001) and disease-free survival (HR, 0.32; 95% CI, 0.19-0.55; P < .001). After adjustment, FLOT remained independently associated with better overall survival (HR, 0.34; 95% CI, 0.16-0.69; P = .003) and disease-free survival (HR, 0.35; 95% CI, 0.19-0.62; P < .001). Recurrence occurred in 13 of 147 patients receiving FLOT (8.8%) compared with 37 of 150 receiving CROSS (24.7%). Distant metastases predominated in the CROSS group (27 of 37 recurrences [70.3%]), whereas recurrence patterns were more heterogeneous after FLOT (locoregional, 2 of 13 recurrences [15.4%]; distant, 2 of 13 recurrences [38.5%]; both, 6 of 13 recurrences [30.8%]). The median (IQR) time to recurrence was longer after FLOT than CROSS (16.8 [12.3-21.5] vs 12.8 [7.1-26.7] months). In subgroup analyses, FLOT was associated with better survival in cN0 or 1 disease (HR, 0.32; 95% CI, 0.15-0.67; P = .002). CONCLUSIONS AND RELEVANCE: In this cohort study, perioperative FLOT in patients achieving pCR for esophageal adenocarcinoma was associated with superior survival, lower recurrence risk, and later recurrence compared with CROSS. These findings suggest the prognostic significance of pCR may vary by neoadjuvant modality and should be interpreted in the context of treatment strategy.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Alhayo S, Chou WK, Giorgi L, et al. FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma. JAMA Surg. 2026. PMID: 42455557. doi:10.1001/jamasurg.2026.2703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。